AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing
In this article:
AbbVie stock slipped Thursday despite a second-quarter beat that included strong Skyrizi sales and a boost to 2024 earnings guidance.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
AbbVie stock slipped Thursday despite a second-quarter beat that included strong Skyrizi sales and a boost to 2024 earnings guidance.